

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA 复星医药

上海復星醫藥(集團)股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a a a P R b C a ab)
(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT

本公司董事會、監事會及全體員工，謹此向廣大股東、債權人、投資者及社會各界人士致以誠摯的問候和衷心的感謝。本報告所載之資料，均經本公司董事會、監事會及全體員工認真核實，確保其真實、準確、完整。本報告所載之資料，均經本公司董事會、監事會及全體員工認真核實，確保其真實、準確、完整。本報告所載之資料，均經本公司董事會、監事會及全體員工認真核實，確保其真實、準確、完整。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang
Chairman

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* for identification purposes only

1. IMPORTANT NOTICE

1. The Board (Board) and the Supervisory Committee (Supervisory Committee) are responsible for the management and supervision of the company's business operations and financial activities. They are required to exercise their duties in a diligent and prudent manner, and to ensure the company's long-term and sustainable development.

2. The Board and the Supervisory Committee shall be composed of members who are independent, objective, and capable of exercising their duties independently. They shall be elected or appointed in accordance with the company's articles of association and the relevant laws and regulations.

3. The Board and the Supervisory Committee shall have the authority to make decisions on the company's major business operations and financial activities. They shall also be responsible for monitoring and evaluating the performance of the company's management and employees, and for reporting to the shareholders.

4. The Board and the Supervisory Committee shall be subject to the supervision and control of the shareholders and the relevant regulatory authorities. They shall also be responsible for ensuring the company's compliance with the relevant laws and regulations.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

1. 2021年3月31日

2021年3月31日

	31 March 2021	31 December 2020	Ratio of change (%)
1. 2021年3月31日	7,144,111,000	7,144,111,000	100%
2. 2021年3月31日	7,144,111,000	7,144,111,000	100%
	Jan - Mar 2021	Jan - Mar 2020	Period-on-period change (%)
1. 2021年3月31日	7,144,111,000	7,144,111,000	100%
	Jan - Mar 2021	Jan - Mar 2020	Period-on-period change (%)
1. 2021年3月31日	7,144,111,000	7,144,111,000	100%
2. 2021年3月31日	7,144,111,000	7,144,111,000	100%
3. 2021年3月31日	7,144,111,000	7,144,111,000	100%
4. 2021年3月31日 (%)	100%	100%	100%
5. 2021年3月31日	7,144,111,000	7,144,111,000	100%
6. 2021年3月31日	7,144,111,000	7,144,111,000	100%

Note 1: 2021年3月31日，本集团的总资产为人民币7,144,111,000元，较2020年12月31日的人民币7,144,111,000元，变动比例为100%。本集团的净资产为人民币7,144,111,000元，较2020年12月31日的人民币7,144,111,000元，变动比例为100%。本集团的总负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的流动负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的非流动负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的总资产、净资产、总负债、流动负债和非流动负债均与2020年12月31日持平。

Note 2: 2021年3月31日，本集团的总资产为人民币7,144,111,000元，较2020年12月31日的人民币7,144,111,000元，变动比例为100%。本集团的净资产为人民币7,144,111,000元，较2020年12月31日的人民币7,144,111,000元，变动比例为100%。本集团的总负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的流动负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的非流动负债为人民币0元，较2020年12月31日的人民币0元，变动比例为100%。本集团的总资产、净资产、总负债、流动负债和非流动负债均与2020年12月31日持平。

3. SIGNIFICANT EVENTS

1. Significant events that have occurred during the reporting period and their impact on the financial statements.

(1) Significant events that have occurred during the reporting period and their impact on the financial statements.

2. Significant events that have occurred during the reporting period and their impact on the financial statements.

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
1. Significant events that have occurred during the reporting period and their impact on the financial statements.	1,111,111,111	1,111,111,111	100.00%	1. Significant events that have occurred during the reporting period and their impact on the financial statements.
2. Significant events that have occurred during the reporting period and their impact on the financial statements.	1,111,111,111	1,111,111,111	100.00%	2. Significant events that have occurred during the reporting period and their impact on the financial statements.
3. Significant events that have occurred during the reporting period and their impact on the financial statements.	1,111,111,111	1,111,111,111	100.00%	3. Significant events that have occurred during the reporting period and their impact on the financial statements.
4. Significant events that have occurred during the reporting period and their impact on the financial statements.	1,111,111,111	1,111,111,111	100.00%	4. Significant events that have occurred during the reporting period and their impact on the financial statements.
5. Significant events that have occurred during the reporting period and their impact on the financial statements.	1,111,111,111	1,111,111,111	100.00%	5. Significant events that have occurred during the reporting period and their impact on the financial statements.

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan – Mar 2021	Jan – Mar 2020		
Revenue	77,711,170.24	77,711,170.24	100.00%	
Cost of sales	47,711,170.24	47,711,170.24	100.00%	
Gross profit	30,000,000.00	30,000,000.00	100.00%	
Operating expenses	20,000,000.00	20,000,000.00	100.00%	
Operating income	10,000,000.00	10,000,000.00	100.00%	
Other income	1,000,000.00	1,000,000.00	100.00%	
Other expenses	1,000,000.00	1,000,000.00	100.00%	
Income before taxes	9,000,000.00	9,000,000.00	100.00%	
Taxes	1,000,000.00	1,000,000.00	100.00%	
Net income	8,000,000.00	8,000,000.00	100.00%	

()

... 7% ...

... Non-public Offering ...

... CSRC ... 《中國證監會行政許可申請受理單》 ... 《中國證監會行政許可項目審查一次反饋意見通知書》 ...

... 7 ...

... 21 Fosun Pharma 01 ... 7% ...

... 2021 Restricted Share Incentive Scheme ...
(16 Fosun Pharma 01) -

... 2021 Restricted Share Incentive Scheme ...
... % ...

...

...

...

...

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Wu Yifang

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海复星医药(集团)有限公司

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	1,123,456,789	1,098,765,432
Accounts receivable	234,567,890	212,345,678
Prepaid expenses and other receivables	123,456,789	112,345,678
Inventory	345,678,901	323,456,789
Other current assets	456,789,012	434,567,890
Non-current assets:		
Property, plant and equipment	567,890,123	545,678,901
Intangible assets	678,901,234	656,789,012
Investments in subsidiaries	789,012,345	767,890,123
Investments in associates	890,123,456	868,901,234
Other non-current assets	901,234,567	879,012,345

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Trade payables	1,234,567,890	1,123,456,789
Accounts payable	987,654,321	876,543,210
Other payables	543,210,987	432,109,876
Short-term borrowings	2,345,678,901	2,234,567,890
Contract liabilities	1,234,567,890	1,123,456,789
Provisions	876,543,210	765,432,109
Other current liabilities	345,678,901	234,567,890
Non-current liabilities:		
Long-term borrowings	3,456,789,012	3,345,678,901
Lease liabilities	2,345,678,901	2,234,567,890
Deferred tax liabilities	1,234,567,890	1,123,456,789
Other non-current liabilities	567,890,123	456,789,012
Equity:		
Share capital	1,234,567,890	1,234,567,890
Reserves	2,345,678,901	2,345,678,901
Other equity	345,678,901	345,678,901
Total	10,000,000,000	10,000,000,000

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海复星医药(集团)有限公司

Items	31 March 2021	31 December 2020
Current assets:		
货币资金	1,123,456,789.12	1,098,765,432.10
应收账款	234,567,890.12	212,345,678.90
预付款项	123,456,789.01	101,234,567.89
其他应收款	345,678,901.23	323,456,789.01
存货	456,789,012.34	434,567,890.12
流动资产合计	2,283,338,371.62	2,169,369,588.02
Non-current assets:		
长期股权投资	123,456,789.01	101,234,567.89
固定资产	234,567,890.12	212,345,678.90
无形资产	345,678,901.23	323,456,789.01
其他非流动资产	456,789,012.34	434,567,890.12
非流动资产合计	1,160,532,592.70	1,071,604,925.92
Current liabilities:		
应付账款	123,456,789.01	101,234,567.89
预收款项	234,567,890.12	212,345,678.90
应付职工薪酬	345,678,901.23	323,456,789.01
应交税费	456,789,012.34	434,567,890.12
其他应付款	567,890,123.45	545,678,901.23
流动负债合计	1,728,382,716.15	1,617,283,826.15
Equity		
股本	100,000,000.00	100,000,000.00
资本公积	200,000,000.00	200,000,000.00
盈余公积	300,000,000.00	300,000,000.00
未分配利润	400,000,000.00	380,000,000.00
所有者权益合计	1,000,000,000.00	980,000,000.00
Total	4,443,870,864.32	4,220,974,513.94

Balance Sheet of the Parent Company (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term debt	1,700,000,000	1,700,000,000
Long-term debt	1,700,000,000	1,700,000,000
Long-term debt	1,700,000,000	1,700,000,000
Long-term debt	1,700,000,000	1,700,000,000
Long-term debt	1,700,000,000	1,700,000,000
Long-term debt	1,700,000,000	1,700,000,000
Equity:		
Share capital	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000
Reserves	1,000,000,000	1,000,000,000

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海医药集团股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	77,411,170.52	47,774,100.57
二、营业成本	77,411,170.52	47,774,100.57
三、营业利润	0.00	0.00
四、营业外收入	471,014,000.00	1,474,100.00
五、营业外支出	471,014,000.00	0.00
六、利润总额	0.00	0.00
七、所得税费用	0.00	0.00
八、净利润	0.00	0.00
九、其他综合收益	0.00	0.00
十、综合收益总额	0.00	0.00
十一、每股收益	0.00	0.00
十二、其他	0.00	0.00
十三、归属于母公司所有者的净利润	0.00	0.00
十四、归属于少数股东的净利润	0.00	0.00
十五、归属于母公司所有者的综合收益总额	0.00	0.00
十六、归属于少数股东的综合收益总额	0.00	0.00
十七、归属于母公司所有者的净利润	0.00	0.00
十八、归属于少数股东的净利润	0.00	0.00
十九、归属于母公司所有者的综合收益总额	0.00	0.00
二十、归属于少数股东的综合收益总额	0.00	0.00
二十一、归属于母公司所有者的净利润	0.00	0.00
二十二、归属于少数股东的净利润	0.00	0.00
二十三、归属于母公司所有者的综合收益总额	0.00	0.00
二十四、归属于少数股东的综合收益总额	0.00	0.00
二十五、归属于母公司所有者的净利润	0.00	0.00
二十六、归属于少数股东的净利润	0.00	0.00
二十七、归属于母公司所有者的综合收益总额	0.00	0.00
二十八、归属于少数股东的综合收益总额	0.00	0.00
二十九、归属于母公司所有者的净利润	0.00	0.00
三十、归属于少数股东的净利润	0.00	0.00
三十一、归属于母公司所有者的综合收益总额	0.00	0.00
三十二、归属于少数股东的综合收益总额	0.00	0.00
三十三、归属于母公司所有者的净利润	0.00	0.00
三十四、归属于少数股东的净利润	0.00	0.00
三十五、归属于母公司所有者的综合收益总额	0.00	0.00
三十六、归属于少数股东的综合收益总额	0.00	0.00
三十七、归属于母公司所有者的净利润	0.00	0.00
三十八、归属于少数股东的净利润	0.00	0.00
三十九、归属于母公司所有者的综合收益总额	0.00	0.00
四十、归属于少数股东的综合收益总额	0.00	0.00
四十一、归属于母公司所有者的净利润	0.00	0.00
四十二、归属于少数股东的净利润	0.00	0.00
四十三、归属于母公司所有者的综合收益总额	0.00	0.00
四十四、归属于少数股东的综合收益总额	0.00	0.00
四十五、归属于母公司所有者的净利润	0.00	0.00
四十六、归属于少数股东的净利润	0.00	0.00
四十七、归属于母公司所有者的综合收益总额	0.00	0.00
四十八、归属于少数股东的综合收益总额	0.00	0.00
四十九、归属于母公司所有者的净利润	0.00	0.00
五十、归属于少数股东的净利润	0.00	0.00
五十一、归属于母公司所有者的综合收益总额	0.00	0.00
五十二、归属于少数股东的综合收益总额	0.00	0.00
五十三、归属于母公司所有者的净利润	0.00	0.00
五十四、归属于少数股东的净利润	0.00	0.00
五十五、归属于母公司所有者的综合收益总额	0.00	0.00
五十六、归属于少数股东的综合收益总额	0.00	0.00
五十七、归属于母公司所有者的净利润	0.00	0.00
五十八、归属于少数股东的净利润	0.00	0.00
五十九、归属于母公司所有者的综合收益总额	0.00	0.00
六十、归属于少数股东的综合收益总额	0.00	0.00
六十一、归属于母公司所有者的净利润	0.00	0.00
六十二、归属于少数股东的净利润	0.00	0.00
六十三、归属于母公司所有者的综合收益总额	0.00	0.00
六十四、归属于少数股东的综合收益总额	0.00	0.00
六十五、归属于母公司所有者的净利润	0.00	0.00
六十六、归属于少数股东的净利润	0.00	0.00
六十七、归属于母公司所有者的综合收益总额	0.00	0.00
六十八、归属于少数股东的综合收益总额	0.00	0.00
六十九、归属于母公司所有者的净利润	0.00	0.00
七十、归属于少数股东的净利润	0.00	0.00
七十一、归属于母公司所有者的综合收益总额	0.00	0.00
七十二、归属于少数股东的综合收益总额	0.00	0.00
七十三、归属于母公司所有者的净利润	0.00	0.00
七十四、归属于少数股东的净利润	0.00	0.00
七十五、归属于母公司所有者的综合收益总额	0.00	0.00
七十六、归属于少数股东的综合收益总额	0.00	0.00
七十七、归属于母公司所有者的净利润	0.00	0.00
七十八、归属于少数股东的净利润	0.00	0.00
七十九、归属于母公司所有者的综合收益总额	0.00	0.00
八十、归属于少数股东的综合收益总额	0.00	0.00
八十一、归属于母公司所有者的净利润	0.00	0.00
八十二、归属于少数股东的净利润	0.00	0.00
八十三、归属于母公司所有者的综合收益总额	0.00	0.00
八十四、归属于少数股东的综合收益总额	0.00	0.00
八十五、归属于母公司所有者的净利润	0.00	0.00
八十六、归属于少数股东的净利润	0.00	0.00
八十七、归属于母公司所有者的综合收益总额	0.00	0.00
八十八、归属于少数股东的综合收益总额	0.00	0.00
八十九、归属于母公司所有者的净利润	0.00	0.00
九十、归属于少数股东的净利润	0.00	0.00
九十一、归属于母公司所有者的综合收益总额	0.00	0.00
九十二、归属于少数股东的综合收益总额	0.00	0.00
九十三、归属于母公司所有者的净利润	0.00	0.00
九十四、归属于少数股东的净利润	0.00	0.00
九十五、归属于母公司所有者的综合收益总额	0.00	0.00
九十六、归属于少数股东的综合收益总额	0.00	0.00
九十七、归属于母公司所有者的净利润	0.00	0.00
九十八、归属于少数股东的净利润	0.00	0.00
九十九、归属于母公司所有者的综合收益总额	0.00	0.00
一百、归属于少数股东的综合收益总额	0.00	0.00

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
I -		
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
(10)		
(11)		
(12)		
(13)		
(14)		
(15)		
(16)		
(17)		
(18)		
(19)		
(20)		
(21)		
(22)		
(23)		
(24)		
(25)		
(26)		
(27)		
(28)		
(29)		
(30)		
(31)		
(32)		
(33)		
(34)		
(35)		
(36)		
(37)		
(38)		
(39)		
(40)		
(41)		
(42)		
(43)		
(44)		
(45)		
(46)		
(47)		
(48)		
(49)		
(50)		
(51)		
(52)		
(53)		
(54)		
(55)		
(56)		
(57)		
(58)		
(59)		
(60)		
(61)		
(62)		
(63)		
(64)		
(65)		
(66)		
(67)		
(68)		
(69)		
(70)		
(71)		
(72)		
(73)		
(74)		
(75)		
(76)		
(77)		
(78)		
(79)		
(80)		
(81)		
(82)		
(83)		
(84)		
(85)		
(86)		
(87)		
(88)		
(89)		
(90)		
(91)		
(92)		
(93)		
(94)		
(95)		
(96)		
(97)		
(98)		
(99)		
(100)		

<i>Legal Representative:</i> Wu Yifang	<i>Chief Financial Officer:</i> Guan Xiaohui	<i>Director of the Accounting Department:</i> Yan Jia
--	--	---

Income Statement of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

人民币千元

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,147,777	747,777
(一) 主营业务收入	1,147,777	747,777
(二) 其他业务收入	-	-
二、营业成本	777,777	777,777
(一) 主营业务成本	777,777	777,777
(二) 其他业务成本	-	-
三、营业利润	370,000	-30,000
(一) 营业毛利	370,000	-30,000
(二) 其他	-	-
四、营业外收入	1,000	1,000
(一) 非流动资产处置损益	1,000	1,000
(二) 其他	-	-
五、营业外支出	1,000	1,000
(一) 非流动资产处置损益	1,000	1,000
(二) 其他	-	-
六、利润总额	369,000	-30,000
(一) 营业利润	370,000	-30,000
(二) 营业外收入	1,000	1,000
(三) 营业外支出	1,000	1,000
七、所得税费用	110,000	110,000
(一) 当期所得税	110,000	110,000
(二) 递延所得税	-	-
八、净利润	259,000	-140,000
(一) 归属于母公司所有者的净利润	259,000	-140,000
(二) 少数股东损益	-	-
九、其他综合收益	-	-
(一) 其他综合收益	-	-
十、综合收益总额	259,000	-140,000
(一) 归属于母公司所有者的综合收益总额	259,000	-140,000
(二) 少数股东综合收益总额	-	-

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
()	1,177,777	1,177,777
()	1,177,777	1,177,777
()	1,177,777	1,177,777
()	1,177,777	1,177,777

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(The figures are in million RMB unless otherwise specified)

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	1,234,567	987,654
Adjustments to reconcile net income to cash flow from operating activities:		
Depreciation and amortization	123,456	109,876
Provision for doubtful accounts	45,678	32,109
Change in accounts receivable	(23,456)	(12,345)
Change in accounts payable	56,789	67,890
Change in prepayments	(12,345)	(8,901)
Change in other receivables	78,901	65,432
Change in other payables	(34,567)	(21,098)
Change in income taxes payable	90,123	78,901
Change in other non-current assets and liabilities	(10,987)	(9,876)
Change in cash and cash equivalents	1,385,216	1,289,130
II. Cash flow generated from investing activities:		
Proceeds from the disposal of non-current assets	123,456	98,765
Proceeds from the disposal of subsidiaries	45,678	32,109
Proceeds from the disposal of financial assets	78,901	65,432
Proceeds from the disposal of other non-current assets	10,987	9,876
Payments for the acquisition of non-current assets	(234,567)	(198,765)
Payments for the acquisition of subsidiaries	(56,789)	(45,678)
Payments for the acquisition of financial assets	(12,345)	(8,901)
Payments for the acquisition of other non-current assets	(8,901)	(7,890)
Change in cash and cash equivalents	(13,681)	(54,152)

Consolidated Statement of Cash Flow (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
III. Cash flow generated from financing activities:		
Increase in short-term debt	1,111,111.11	1,111,111.11
Decrease in short-term debt	(1,111,111.11)	(1,111,111.11)
Increase in long-term debt	1,111,111.11	1,111,111.11
Decrease in long-term debt	(1,111,111.11)	(1,111,111.11)
Increase in equity	1,111,111.11	1,111,111.11
Decrease in equity	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
Decrease in cash and cash equivalents	(1,111,111.11)	(1,111,111.11)
IV. Effects of exchange rate fluctuations on cash and cash equivalents	1,111,111.11	1,111,111.11
V. Net increase of cash and cash equivalents	1,111,111.11	1,111,111.11
Increase in cash and cash equivalents	1,111,111.11	1,111,111.11
VI. Closing balance of cash and cash equivalents	1,111,111.11	1,111,111.11

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Statement of Cash Flow of the Parent Company

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(The figures are in thousands of RMB)

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	1,700,000	1,100,000
Depreciation and amortization	1,200,000	1,100,000
Provision for bad debts	100,000	100,000
Provision for doubtful accounts	100,000	100,000
Provision for employee benefits	100,000	100,000
Provision for income taxes	100,000	100,000
Change in accounts receivable	(100,000)	(100,000)
Change in accounts payable	100,000	100,000
Change in prepayments	100,000	100,000
Change in other receivables	100,000	100,000
Change in other payables	100,000	100,000
Change in contract liabilities	100,000	100,000
Change in other non-current assets	100,000	100,000
Change in other non-current liabilities	100,000	100,000
Change in cash and cash equivalents	1,700,000	1,100,000
II. Cash flow generated from investing activities:		
Capital expenditures	(1,000,000)	(1,000,000)
Acquisition of subsidiaries	(1,000,000)	(1,000,000)
Disposal of subsidiaries	100,000	100,000
Disposal of long-term investments	100,000	100,000
Disposal of other non-current assets	100,000	100,000
Disposal of other non-current liabilities	100,000	100,000
Change in cash and cash equivalents	(1,000,000)	(1,000,000)
